The Aplastic Anemia market presents opportunities in novel therapies, with 5+ companies and 8+ drugs in various development stages. Key focus is on innovative treatment approaches, partnerships, and ...

The signs of anemia can be subtle and easy to pass off as overwork or not getting enough sleep. But a Temple Health family ...

The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have ...

Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...

Akebia Therapeutics has scrapped plans for trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo, the company said.

Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding ...

Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. ・The company said on Tuesday that it met ...